Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-fracture Treatment Among Commercially Insured Postmenopausal Women in the United States.
Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States (ACR)
Challenge
Post-fracture treatment rates among commercially insured post-menopausal women in the US have been declining, but contemporary trends in subsequent fracture risk and post-fracture treatment utilization among younger commercially insured women had not been characterized.
Solution
Target RWE and Amgen researchers analyzed a large commercial insurance claims database to describe yearly fracture incidence rates, subsequent fracture risk, and post-fracture pharmacologic treatment patterns among post-menopausal women from 2012 to 2021.
Impact
Demonstrating persistently low post-fracture treatment rates in commercially insured women provides Amgen with compelling real-world evidence of a treatment gap supporting the commercial and clinical case for osteoporosis therapy.